Tick-borne Encephalitis

Through an infected tick's bite, the tick-borne encephalitis virus is transmitted and results in tick borne encephalitis. Positioned as pioneers in TBE vaccine and therapeutic advancement, our company extends a holistic range of services to tackle the intricate hurdles posed by this malady.

Overview of Tick-borne Encephalitis

Tick-borne encephalitis (TBE) is an acute viral infection with possible severe complications of inflammation of the central nervous system. It result from one of the three listed closely related genetic variants of TBEV: European (TBEV-Eu), Siberian (TBEV-Sib), or Far Eastern (TBEV-FE). In nature, the virus is maintained in a cycle between certain species of ticks, mainly of the Ixodes and some small mammals such as rodents. In humans it is more often the case of being infected by tick bites, although the use of infected dairy products is another well-known way of getting the disease.

Fig.1 Diagnosis and therapeutics of Tick-borne encephalitis (TBE). (Riccardi N., et al., 2019)

Vaccine Development for Tick-borne Encephalitis

Immunization against TBE is one of the cleverest approaches in addressing the disease. Numerous vaccines have been produced and vaccines exist against it, most of which employ the inactivated whole virus particles technique. They are known to be quite effective at generating strong immune responses to TBEV and, therefore, there is a substantial drop in TBE cases in the affected regions.

• FSME-Immun: It is manufactured by Pfizer and is given in a 3 dose schedule with TBEV boosters recommended every 5 years. This vaccine is cross reactive and is predicated on the European subtype of TBEV.
• Encepur: Also produced by Bavarian Nordic, Encepur's target and schedule of administration is almost identical to that of FSME-Immun. It is based on the European subtype.
• TBE-Moscow and EnceVir NP0: These vaccines are produced in Russia. EnceVir NP0 is of the Far Eastern subtype of TBEV and it is given in a two dose schedule.

Table 1 Summary of TBE vaccines. (Phipps L. P., et al., 2022)

Therapeutics Development for Tick-borne Encephalitis

The maintenance of a supportive care is the current standard of TBE management and using immunization with, there is a significant absence of certain antiviral treatment that is still necessary. Development of the targeted therapies, however, appears to be an important focus of constant attention.

Our Services

In our company, we take active part in the creation of new vaccines and therapeutics for TBE or tick-borne encephalitis, which is becoming a more significant public health issue. Our services are specialized for catering different biopharmaceutical partners at each stage of the R&D process.

Vaccine Development

• Live-attenuated Vaccine
• Inactivated Vaccine
• Toxoid Vaccine
• Viral Vector Vaccine
• Virus-like Particles Vaccine
• Protein Subunit Vaccine
• mRNA Vaccine
• DNA Vaccine

Therapeutic Development

• Small Molecule Drug Development Services
• Therapeutic mRNA Development Services
• Therapeutic Antibody Development Services
• Cell Therapy Development Services

Disease Models

• Subcutaneous Inoculation of TBEV (or OHFV) African Green Monkey Models
• Subcutaneous Inoculation of Different Strains of TBEV Mouse Models

Preclinical Research

• Pharmacodynamics Study Services
• Pharmacokinetics Study Services
• Drug Safety Evaluation Services
• Customized Research Services

Our preclinical research capabilities encompass in vitro studies, animal model development, and specialized assays to evaluate the safety, immunogenicity, and efficacy of TBE vaccine and therapeutic candidates. We leverage our expertise in virology, immunology, and pharmacology to provide comprehensive preclinical data packages to support the advancement of promising TBE interventions. If you are interested in our services, please feel free to contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.